FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  BALEN JOHN V						2. Issuer Name and Ticker or Trading Symbol Cardlytics, Inc. [ CDLX ]									ationship of Reporti all applicable) Director		ing Person(s) to Is		
	NAAN PAR	TNERS	Middl	e)		Date of 8/12/20		t Trai	nsaction (Month/Day/Year)						Officer (give title below)		Other below		(specify )
285 RIVERSIDE AVENUE, SUITE 250  (Street)  WESTPORT CT 06880					4.	4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line)	Forn	n filed by Or	t/Group Filing (Check App		son
(City)			Zip)		-										Pers		More than One Reporting		
		Tabl	eI-	Non-Deriv	/ativ	e Sec	uritie	s A	cqui	red,	Disposed	of, or	Benefi	cially	Owne	ed			
1. Title of Security (Instr. 3)			2. Transaction Date (Month/Day/Y		Execution if any	A. Deemed xecution Date, any Month/Day/Year)		3. Transaction Code (Instr. 8)				5)	5. Amount of Securities Beneficially Owned Followin		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
							[	Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)	
Common Stock				08/12/202	19	9			S		84,185	D	\$31.79	986 <sup>(1)</sup>	10	103,498			See Footnote <sup>(2)</sup>
Common	Stock			08/12/202	19				S		2,600	D	\$33.1	05 <sup>(3)</sup>	10	0,898			See Footnote <sup>(2)</sup>
Common Stock			08/13/2019					S		100,898	D	\$31.99	\$31.9986 <sup>(4)</sup>		0			See Footnote <sup>(2)</sup>	
Common	Stock														15,	, <mark>721</mark> <sup>(5)</sup>	]	D	
		Та	ble								sposed of, s, converti				wned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exed if an			action (Instr.	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Expiration (Month/Day			Amou Secur Unde Deriva Secur	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)			9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	Owne Form Direct or Ind (I) (In:	wnership	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exe	e rcisab	Expiration le Date	Title	Amoun or Numbe of Shares						

## **Explanation of Responses:**

- 1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$31.75 \$32.185, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 2. The reportable securities are held directly by Canaan VIII, LP (the "Canaan Fund"). Canaan Partners VIII LLC ("Canaan VIII" and together with the Canaan Fund, the "Canaan Entities") is the sole general partner of the Canaan Fund. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan VIII, collectively. John Balen, a manager and member of Canaan VIII, serves as the representative of the Canaan Entities on the Issuer's board of directors. Mr. Balen disclaims beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest, if any, in such securities by virtue of the limited liability company interests he owns in Canaan VIII.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.00 \$33.21, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$31.75 \$32.50, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 5. Includes 3,074 and 1,392 shares received by the Reporting Person pursuant to pro rata distributions, for no consideration, by the Canaan Fund on June 20, 2019 and July 24, 2019, respectfully. The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended

## Remarks:

/s/ John V. Balen

08/14/2019

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.